These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15198507)

  • 1. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).
    Rowland M; Balant L; Peck C
    AAPS PharmSci; 2004 Feb; 6(1):E6. PubMed ID: 15198507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-based pharmacokinetics in drug development and regulatory science.
    Rowland M; Peck C; Tucker G
    Annu Rev Pharmacol Toxicol; 2011; 51():45-73. PubMed ID: 20854171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic (PBPK) modeling in children.
    Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
    Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.
    Edginton AN; Theil FP; Schmitt W; Willmann S
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1143-52. PubMed ID: 18721109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
    Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report.
    Wu F; Mousa Y; Raines K; Bode C; Tsang YC; Cristofoletti R; Zhang H; Heimbach T; Fang L; Kesisoglou F; Mitra A; Polli J; Kim MJ; Fan J; Zolnik BS; Sun D; Zhang Y; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):585-597. PubMed ID: 36530026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
    Block M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
    Corriol-Rohou S; Cheung SYA
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
    Bouzom F; Ball K; Perdaems N; Walther B
    Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.
    McLanahan ED; El-Masri HA; Sweeney LM; Kopylev LY; Clewell HJ; Wambaugh JF; Schlosser PM
    Toxicol Sci; 2012 Mar; 126(1):5-15. PubMed ID: 22045031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole body pharmacokinetic models.
    Nestorov I
    Clin Pharmacokinet; 2003; 42(10):883-908. PubMed ID: 12885263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.
    Abend A; Heimbach T; Cohen M; Kesisoglou F; Pepin X; Suarez-Sharp S
    AAPS J; 2018 Apr; 20(3):60. PubMed ID: 29633092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Have physiologically-based pharmacokinetic models delivered?
    Edginton AN; Joshi G
    Expert Opin Drug Metab Toxicol; 2011 Aug; 7(8):929-34. PubMed ID: 21762039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.
    Wagner C; Zhao P; Pan Y; Hsu V; Grillo J; Huang SM; Sinha V
    CPT Pharmacometrics Syst Pharmacol; 2015 Apr; 4(4):226-30. PubMed ID: 26225246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.
    Charnick SB; Kawai R; Nedelman JR; Lemaire M; Niederberger W; Sato H
    J Pharmacokinet Biopharm; 1995 Apr; 23(2):217-29. PubMed ID: 8719238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings of a workshop on DNA adducts: biological significance and applications to risk assessment Washington, DC, April 13-14, 2004.
    Sander M; Cadet J; Casciano DA; Galloway SM; Marnett LJ; Novak RF; Pettit SD; Preston RJ; Skare JA; Williams GM; Van Houten B; Gollapudi BB
    Toxicol Appl Pharmacol; 2005 Oct; 208(1):1-20. PubMed ID: 16164957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.